A significant amount of targeted drug had been developed in the recent years. Since the targeted therapeutics have far fewer side effects and more effective than chemotherapy drugs, millions of cancer patients benefit from the targeted drugs. There are not only new drugs targeting the cancer driving genes, but also targeting the microenvironment and immune system. The discovery of new anti-cancer drug targets provide constantly continuous energy and driving force to the new therapeutic strategies, drug discovery and development.
LIDE provides 4 platforms to enhance the new drug target Identification, Functional Genomics Imaging (FGI), classic bioinformatics analysis, pro-siRNA library screening and genome-wide CRISPR/Cas9 library screening.